Metastatic cell migration and invasion are regulated by altered adhesion-mediated signaling to the actin-based cytoskeleton via activated Src-FAK complexes. Src-suppressed C-kinase substrate (SSeCKS, the rodent orthologue of human Gravin/AKAP12), whose expression is downregulated by oncogenic Src and in many human cancers, antagonizes oncogenic Src pathways including those driving neovascularization at metastatic sites, metastatic cell motility and invasiveness. This is likely manifested through its function as a scaffolder of F-actin and signaling proteins such as cyclins, calmodulin, protein kinase C and A. Here we show that in contrast to its ability to inhibit haptotaxis, SSeCKS increased prostate cancer cell adhesion to fibronectin and type I collagen in a FAK-dependent manner, correlating with a relative increase in FAK poY397 levels. In contrast, SSeCKS suppressed adhesion-induced Src activation (Src poY416 ) and phosphorylation of FAK at Y925, a known Src substrate site. SSeCKS also induced increased cell spreading, cell flattening, integrin b1 clustering and formation of mature focal adhesion plaques. An in silico analysis identified a Src-binding domain on SSeCKS(aa 153-166) that is homologous to the Src-binding domain of caveolin-1, and this region is required for SSeCKS-Src interaction, for SSeCKS-enhanced Src activity and sequestration to lipid rafts and for SSeCKS-enhanced adhesion of MAT-LyLu and CWR22Rv1 prostate cancer cells. Our data suggest a model in which SSeCKS suppresses oncogenic motility by sequestering Src to caveolin-rich lipid rafts, thereby disengaging Src from FAK-associated adhesion and signaling complexes.
INTRODUCTION
Metastasis, recurrence and drug-resistance remain the major contributors to cancer-related mortality, spurring efforts to identify therapies that specifically target the pathways that drive these parameters of malignancy. 1 Members of the Src tyrosine kinase family are known to be overexpressed and/or activated in many primary human cancers, typically through the activation of upstream growth factor receptor tyrosine kinases. 2 However, the coincident activation of parallel oncogenic pathways suggests that Src tyrosine kinase family might be poor therapeutic targets in primary cancers. 3, 4 In contrast, there is a growing appreciation for the critical role played by Src tyrosine kinase family in controlling several parameters of cancer metastasis, such as tumor invasiveness and neovascularization at distal sites, [5] [6] [7] [8] and drug resistance. [9] [10] [11] The oncogenic potential of Src and Ras requires both potentiation of enzymatic activities (tyrosine kinase and GTPase functions, respectively) and specific localization to membrane sites (myristylation and palmitylation, respectively). [12] [13] [14] [15] For example, mutation of Src's N-terminus to prevent myristylation ablates its oncogenic activity, even in the context of a constitutively activated kinase domain. 16 In contrast, splicing this myristylation signal onto AKT facilitates its membrane association and oncogenic activity. 17 Indeed, Src requires N-terminal myristylation in order to enrich in specific lipid-raft membrane domains such as caveolae. 18, 19 The complex formed between caveolin-1 (Cav-1), Src, second-messenger lipids and growth factor receptor tyrosine kinases is thought to mediate normal mitogenic downstream signals, endocytosis, cell-cell adhesion and interaction of the actin-based cytoskeleton with mechano-responsive structures on the plasma membrane. 20, 21 Although many cancers exhibit Cav-1 downregulation, the upregulation of Cav-1 in other cancers has been tied to increased oncogenic motility and invasiveness. 21 A very recent model suggests that phosphorylation of Cav-1 by Src on Y14 enables a dynamic, Rac1-dependent transient translocation of Cav-1 from caveolae to focal adhesions, whereupon the dephosphorylation and subsequent degradation of Cav-1 facilitates focal adhesion turnover and cell motility. 22 Thus, Src-induced oncogenic motility may be facilitated by the increased rate of this pathway, correlating with a net downregulation of Cav-1 levels.
SSeCKS (Src-suppressed C-kinase substrate), the rodent orthologue of human Gravin/AKAP12, seems to function as a metastasis suppressor via its ability to differentially scaffold signaling proteins such as protein kinase C and A, calmodulin and cyclins. 23 SSeCKS also participates in the control of cytoskeletal reorganization associated with motility, most likely facilitated by domains that link it to both plasma membrane and cytoskeletal sites. Plasma membrane association is controlled by N-terminal myristylation and three N-terminal phosphoinositol phosphate-binding sites. 24 SSeCKS/AKAP12 expression is often downregulated in human cancers, and it is especially downregulated due to promoter hypermethylation in metastatic lesions. 23 The reexpression of SSeCKS in MAT-LyLu (MLL) prostate cancer cells had little effect on the growth of primary-site tumors, but it suppressed the growth of spontaneous pulmonary metastases in part, by inhibiting tumorencoded vascular endothelial growth factor secretion, thereby inhibiting neovascularization at metastatic sites. 25 SSeCKS also inhibits oncogenic motility and invasiveness by disengaging growth-factor-activated Src from activating the protein kinase C-Raf-MEK-ERK pathways that control the formation of podosome/ invadosome structures and that upregulate the expression/ secretion of matrix metalloproteinases. Interestingly, Src autophosphorylation and substrate phosphorylation activity are not inhibited by SSeCKS, and taken together with the finding that SSeCKS alters actin-based cytoskeletal architecture, these data suggest that SSeCKS inhibits Src oncogenic signaling by physically scaffolding it away from downstream signal mediators.
Here we demonstrate the mechanism by which SSeCKS increases FAK-dependent cell adhesion to and spreading on fibronectin (FN) and type I collagen. SSeCKS-enhanced adhesion correlated with increased clustering of integrin b1 and formation of mature focal adhesion plaques. SSeCKS enhanced relative adhesion-induced FAKpoY397 levels, yet suppressed phosphorylation at FAKY925, a known Src substrate site, 26 suggesting that Src is disengaged by SSeCKS from normal FAK/Src complexes. Consistent with this notion, we show that a direct binding between Src and SSeCKS via a domain (aa 153-166) homologous to the Src-binding site on Cav-1 27 likely facilitates the enrichment of Src to caveolin-rich lipid rafts, concomitant with a relative increase in Cav-1 poY14 levels in these membrane domains. Our findings strongly suggest that SSeCKS attenuates the ability of Src to induce metastatic progression by directly scaffolding Src pools from FAK complexes to lipid rafts, effectively suppressing formation of constitutive FAK/Src complexes that promote downstream signaling and the cytoskeletal pathways.
RESULTS

SSeCKS-induced cell flattening and chemotaxis inhibition correlates with increased cell adhesion and spreading
Our previous data indicated that in addition to its ability to suppress metastasis in vivo by inhibiting tumor-derived expression of vascular endothelial growth factor, 25 SSeCKS also suppressed chemotaxis and oncogenic invasiveness. 28 These functions and cell adhesion are governed by dynamic changes in actin cytoskeletal remodeling, 29 and indeed, SSeCKS induces these changes in the context of cell flattening. 23 Thus, we addressed whether SSeCKS could also alter adhesion and spreading when reexpressed in MLL prostate cancer cells. We confirmed the coincident effects of cell flattening and chemotaxis inhibition using MLL cells engineered for tetracycline-regulated (tet OFF ) SSeCKS reexpression (MLL/tet-SSeCKS), 30 demonstrating a dosedependent decrease in chemotaxis concomitant with cell flattening ( Supplementary Figures S1a and b ) and the production of exaggerated pseudopodia projections ( Figure 1a ). These data are consistent with our previous demonstrations that SSeCKS can normalize cytoskeletal structures, such as actin stress fibers and mature focal adhesion plaques, and inhibit oncogenic motility parameters when reexpressed in Src-or Ras-transformed cancer cells. 31, 32 We then addressed whether SSeCKS might also affect cell adhesion. Therefore, MLL/tet-SSeCKS cells grown in the presence or absence of tet ( À or þ SSeCKS, respectively) were adhered to extracellular matrix protein (ECM)-coated plates, and both spreading and short-term adherence were assessed. SSeCKS induced 3.6-or 10-fold greater spreading activity on FN or type I collagen, respectively ( Figure 1b ). In contrast, SSeCKS had no effect on cell spreading on vitronectin-or laminin-coated plates. Similar results were produced using long-term adhesion assays onto ECM-coated plates (Figure 1c ), namely a dose-dependent increase in SSeCKS-induced adhesion to FN or type I collagen, but not to vitronectin or laminin. The SSeCKS-enhanced adhesion to FN was accompanied by increased cell flattening ( Figure 1d ). Consistent with the notion that tumor cells have increased integrin-mediated cell migration (haptotaxis) to facilitate transverse migration through basement membranes, 33 SSeCKS suppressed haptotactic motility towards FN-and type I collagen-, but not to vitronectin-or laminin-coated membranes (Figure 1e ).
SSeCKS induces integrin b1 clustering
The ability of integrins to participate in cell-cell and cell-ECM interactions facilitates the altered adhesion and motility parameters that characterize cancer and metastatic cells, especially as this relates to the metastasis-associated differential expression of specific integrins 34 and epithelial-to-mesenchymal transition. 35 Moreover, integrins transduce adhesion-mediated signals to the actin cytoskeleton via Src-FAK complexes in focal adhesions. 36 Based on the ability of SSeCKS to induce adhesion on FN (Figure 1c ), which involves b1 integrin, 37 and based on previous data demonstrating activated b1 integrin in MLL prostate cancer cells, 38 we addressed whether SSeCKS reexpression alters b1 levels. The relative levels of mature b1 were unaffected by SSeCKS reexpression in MLL/tet-SSeCKS cells, although SSeCKS slightly decreased the relative levels of uncleaved ('pre') b1 (Figure 2a ). Thus, the ability of SSeCKS to increase adhesion to FN is not due to overall changes in b1 expression. However, SSeCKS reexpression facilitated FN-induced b1 integrin clustering (as evidenced by punctate vs homogeneous cytoplasmic b1 staining) as well as the formation of FAK-and vinculin-containing focal adhesion plaques and F-actin stress fibers ( Figure 2b ). These effects were concomitant with significant SSeCKS-induced cell flattening. Attempts to demonstrate SSeCKS association with FAK or b1 using co-immunoprecipitation (IP) experiments were unsuccessful (data not shown). Taken together, these data suggest that SSeCKS facilitates adhesion on FN by remodeling b1 integrin/FAK complexes as well as their interaction with the actin-based cytoskeleton.
SSeCKS-enhanced adhesion on FN is FAK-dependent
Integrin-mediated adhesion and motility signaling is regulated through the transient recruitment and activation of FAK-Src signaling complexes. [39] [40] [41] To address whether FAK activity is critical to the SSeCKS-induced enhancement of FN-based adhesion, FAK þ / þ and FAK À / À mouse embryo fibroblasts were cotransfected with pEGFP plus either an SSeCKS expression plasmid or empty vector, and 40 h later, green fluorescent proteinpositive cells were scored for their ability to adhere to FN-coated plates. The expression level of endogenous SSeCKS was roughly 5-fold higher in FAK À / À vs. FAK þ / þ cells ( Figure 3a ), and this correlated with 43-fold higher adhesion of FAK À / À (vector) cells than that of FAK þ / þ (vector) cells on all concentrations of FN tested (Figure 3b ). The higher levels of ectopic SSeCKS expression in FAK À / À cells did not increase adhesion (Figure 3b ), suggesting that the higher basal SSeCKS levels in these cells may already be functionally saturated. In contrast, the ectopic expression of SSeCKS in FAK þ / þ cells increased adhesion two-to three-fold over varying FN concentrations (Figure 3b ), paralleling the effect of either stable or transient SSeCKS expression in MLL cells (Figures 1c and 3c , respectively). The coexpression of MLL cells with SSeCKS and FRNK, a natural FAK antagonist, 42 suppressed the enhanced adhesion, whereas substitution of an inactive FRNK mutant, FRNK S1034 ('FRNKm'), negated the inhibitory effect of FRNK ( Figure 3c ). As a control, we showed that the relative expression levels of hemagglutinin (HA)-tagged FRNK and FRNK S1034 were similar in the transfected MLL cells ( Figure 3d ).
FAK activity is thought to control adhesion turnover because FAK À / À mouse embryo fibroblasts have increased numbers of vinculin-associated focal adhesions and display increased cell spreading. 43 After adherence-induced integrin clustering, FAK autophosphorylates at Y397, forming an SH2 binding site for the recruitment of Src. The reciprocally activating FAK-Src complex induces the remodeling of the actin cytoskeleton that controls cell adhesion and motility. 44 The dependence of this signaling on Src is evidenced by findings that motility induced by transgenic FAK expression in FAK-null fibroblasts is impaired by Src inhibition 45 and that activated Src rescues cell spreading in FAK À / À cells. 46, 47 We investigated whether the effects of SSeCKS on increased adhesion were mediated through FAK activation. Thus, serum-starved MLL/tet-SSeCKS grown overnight in the presence or absence of tet were either allowed to adhere to FN or kept in suspension ('sus'). SSeCKS induced an increase in the relative adhesion-induced level of FAK autophosphorylation (Figure 4a ). In contrast, SSeCKS decreased relative levels of adhesion-induced Src autophosphorylation (poY416), as well as phosphorylation on FAK at a major Src substrate site, Y925 48 (Figure 4a ). The relative phosphorylation of FAK-Y861 26 was unaffected by SSeCKS when normalized to total FAK protein levels. Adherence-induced Mek activation, as demonstrated by relative phospho-Mek1/2 levels, was decreased by SSeCKS, paralleling the effect we showed previously by SSeCKS on serum-induced Mek activation. 28 A failure to phosphorylate FAK Y925 would prevent the formation of the SH2mediated binding site for Grb2, and thus prevent activation of Mek/Erk signaling associated with metastatic progression. 49 Taken together with the data in Figure 2b , these data suggest that SSeCKS interrupts adhesion-induced FAK-Src complex formation, disengaging it from both oncogenic actin cytoskeletal remodeling and activation of Mek/Erk signaling. This notion is backed up by the demonstration that SSeCKS reexpression decreases the amount of Src associating with FAK in co-IPs following adhesion to FN (Figure 4b ).
SSeCKS may alter Src-FAK complex formation by directly scaffolding Src
Trevino et al. 7 recently reported that the siRNA-mediated knockdown of Src had little effect on primary tumor growth but greatly suppressed the formation of metastases, consistent with the known roles for Src in regulating oncogenic cell migration and invasiveness. 2, 12 SSeCKS, which is known to function as an antagonist of Src-induced oncogenic growth, 31 did not alter the proliferation of MLL cells, the overall level of Src-induced substrate phosphorylation or phosphorylation of specific Src substrates such as p130Cas (Supplementary Figure S2) or Shc. 28 This agrees with our previous results showing that SSeCKS reexpression could inhibit Srcinduced anchorage and growth-factor independence and Matrigel invasiveness without affecting Src tyrosine kinase activity. 31, 50 Figure S3a ) and showed that Ni 2 þ beads charged with these proteins retained full binding activity to Src (Figure 5c ). This strongly suggests that the SSeCKS-Src interaction is not mediated through a classic SH3/ ligand interaction, agreeing with the analysis that the SSeCKS 12 PxxP 15 sequence does not conform to known SH3 ligand constraints (personal communication, Kalle Saksela).
In silico analysis identified an SSeCKS sequence, 154 FKKVFKFVGFKTVK 165 , that is homologous to the motif, FxxxFxFxxFxx (F: hydrophobic residues), in Cav-1 (residues 82-101: DGIWKASFTTFTVTKYWFYR). This so-called caveolin-scaffolding domain facilitates direct binding to H-Ras, Src family tyrosine kinases, protein kinase C isoforms and the epidermal growth factor receptor, 52 modulating at plasma membrane sites their roles in controlling oncogenic cell adhesion and migration. 53 Deletion of aa 153-166 abrogated the ability of glutathione S-transferase (GST)-SSeCKS(aa 2-274) protein (Supplementary Figure S3a ) to pull down Src from cell lysates (Figure 5d ). Furthermore, the ability of purified His-Src and GST-SSeCKS (aa 2-274) to efficiently bind each other in reciprocal co-IP assays required the putative Src-binding domain in aa 153-166 ( Figure 5e ). Importantly, although ectopic full-length SSeCKS could induce FN-mediated adhesion in MLL cells and in the human prostate cancer cell line, CWR22Rv1, SSeCKS deletion of the aa 153-166 domain (Supplementary Figure S3b) failed to enhance attachment (Figure 5f ). These data indicate that SSeCKS likely binds Src via its N-terminal Cav-1-like motif and not via the putative PxxP ligand motif, and that an SSeCKS-Src interaction facilitates the enhanced attachment on FN by prostate cancer cells.
SSeCKS sequesters Src from FAK-Src complexes
Besides the caveolin-scaffolding domain, Src association with caveolae is facilitated by its N-terminal myristylation, 15 and indeed, Cav-1 was first identified as a v-Src substrate. 54, 55 SSeCKS is also myristylated at its N-terminus, 56 and therefore, it is conceivable that SSeCKS may function in a similar fashion to scaffold Src to lipid-raft sites (and away from sites of adhesionmediated FAK activation such as focal adhesion plaques) via its caveolin-scaffolding-like domain. This would be especially significant in that caveolae coordinate cell migration by enriching major signaling mediators in plasma membrane microdomains in a spatiotemporal fashion. 57 To address this, we plated serum-starved MLL/tet-SSeCKS cells grown overnight in the presence or absence of tet onto FN for 60 min (vs suspended cells) and then subjected Triton X-100 lysates to sucrose density gradients. Lipid rafts, as marked by the enrichment of Cav-1, are typically found in lighter membrane fractions 4-5 in adherent cells but in heavier fractions in suspended MLL cells (Figure 6a ). SSeCKS did not significantly alter the localization of Cav-1 in adherent (c) RIPA lysates of MLL/tet-SSeCKS cells grown in the presence or absence of tet ( À or þ SSeCKS, respectively) and then plated onto FN for various times as in panel B were immunoprecipitated with FAK Ab-beads (1 mg protein/IP) and then analyzed for Src or FAK by IB.
cells, but did shift Cav-1 to lighter fractions 4 and 5 in suspended cells. This corresponded to a similar shift of the ectopic SSeCKS in both suspended and adherent cells to lighter fractions (fraction 5 for the suspended cells and fractions 4-5 for the adherent cells). Although SSeCKS had no effect of FAK localization in either adherent or suspended cells (with FAK enriching in fractions 6-9), SSeCKS induced a shift of Src in both suspended and adherent cells to lighter fractions (5 in suspended cells and 4-5 in adherent cells). Thus, SSeCKS induced a movement of some Src from fractions containing FAK to those containing Cav-1.
SSeCKS also induced increased relative Cav-1 poY14 levels in adherent cells, specifically a two-fold increase in fractions 4 and 5, which are enriched with ectopic SSeCKS and Src (Figure 6a ). A similar increase in relative Cav-1 poY14 levels was detected in total cell lysates of adherent MLL/tet-SSeCKS cells (Supplementary Figure S4 ; compare lanes C and D). As a control, treatment with methyl-b-cyclodextrin, a cholesterol-binding compound that dissolves caveolae, 58 induced movement of Cav-1 and Cav-1 poY14 into slightly heavier fractions (out of fraction 3 or 4, respectively, in adherent cells). Methyl-b-cyclodextrin induced a Figure S5) . These data suggest that SSeCKS scaffolds Src to caveolin-rich lipid rafts in adherent cells, resulting in increased Cav-1 tyrosine phosphorylation. Consistent with this model, the ability of SSeCKS to induce Src activity in lipid rafts and at general membrane sites using fluorescence resonance energy transfer (FRET) sensors 59, 60 required SSeCKS's Src-binding domain (Figure 6b ; Supplementary Figure S6 ). In contrast, SSeCKS did not activate FAK in lipid rafts, consistent with the notion that FAK remains enriched in focal adhesions during adhesion and that SSeCKS does not directly regulate its activity.
DISCUSSION
Although there are rare cases of breast and colon cancers expressing Src-containing activating mutations akin to the socalled 'viral Src signature', 61, 62 Src likely drives oncogenic progression by virtue of being overexpressed or activated by upstream growth factor receptors. 61, 62 Many parameters of metastasis seem to be dependent on Src signaling, such as oncogenic motility, recruitment of mural cells to metastatic niches and neovascularization at metastatic sites, 6 leading to a renewed focus on Src as a therapeutic target in advanced cancer. Our data indicate that SSeCKS functions as an especially potent suppressor of Src's metastasis-promoting functions, even though SSeCKS does not inhibit Src's intrinsic tyrosine kinase activity. 50, 65 Here, we show that SSeCKS attenuates adhesion-induced activation of Src (based on poY416 levels), but more potently suppresses phosphorylation of FAK Y925 , a known Src substrate site, following FN-mediated adhesion. This would prevent the formation of a ligand site for Grb2-SH2 and the subsequent activation of the downstream Mek-Erk pathways. These data are similar to those showing that SSeCKS suppresses growth factorinduced oncogenic invasiveness pathways through the disengagement of Src from the Mek-Erk pathways. 28 Our data demonstrate concurrence between SSeCKS-induced cell flattening, previously shown as mediated through the remodeling of the actin-based cytoskeleton, 66 increased cell adhesion to and spreading on FN, and increased relative FAK autophosphorylation levels. The ability of SSeCKS to decrease adhesion-induced Src activation and relative FAK poY925 levels suggests that SSeCKS disengages Src from the FAK/Src complexes that drive oncogenic adhesion signals, concomitant with decreased focal turnover. In a previous study, 28 SSeCKS did not alter serum-induced FAK or Src activation levels, but it did suppress the relative levels of Mek activation, again, suggesting that SSeCKS disengages Src from downstream signaling, in this case, the pathways driving oncogenic invasiveness and chemotaxis. In this model, the SSeCKS-induced disengagement of Src would increase the relative level of adhesion-activated FAK (reflected in relative FAK poY397 levels). This agrees with previous data from Yeo et al. 67 showing that expression of a Src SH2domain mutant, R175L, which is prevented from binding to autophosphorylated FAK, results in higher relative adhesioninduced FAK poY397 levels.
Although SSeCKS might alter Src compartmentalization indirectly through its ability to remodel the cytoskeleton, we addressed whether there is a direct scaffolding function for Src, made likely by previous data that the proline 15/16 residues of Gravin are required for its association with Src in complex containing b 2 adrenergic receptor. 51 Indeed, our data indicate that SSeCKS binds Src directly through an N-terminal fragment (aa 2-274). However, in our hands, both this fragment and a P15A mutant bound equally well to Src, suggesting that the this is not a classic SH3/ PxxP interaction. A subsequent in silico analysis identified another motif within the SSeCKS N-terminus (aa 153-166) that is homologous to the caveolin-binding domain for Src. Importantly, deletion of this domain abrogated SSeCKS-Src association and the ability of SSeCKS to enhance Src activity in lipid rafts as well as adhesion of prostate cancer cells.
There is a growing evidence that the ability of Src to induce oncogenic signaling for proliferation, cell survival and cell motility might relate to an imbalance in its shuttling between lipid rafts and cell-cell or focal adhesion complexes. For example, sequestration of Src by the Csk-binding protein, Cbp, to lipid rafts suppresses oncogenic transformation. 68 A recent study by Nethe and Hordijk 22 suggests that during normal adhesion signaling, Src shuttling to lipid rafts induces Cav-1 Y14 phosphorylation followed by a secondary Rac1-dependent translocation of Src/Cav-1 poY14 to FAK-enriched focal adhesion plaques. A subsequent dephosphorylation and degradation of Cav-1 then triggers focal adhesion turnover associated with cell motility. Another layer of control is added by the findings of Del Pozo et al., 69 who showed that cell detachment induces translocation of Cav-1 poY14 to caveolae followed by caveolar endocytosis. Figure 6 . SSeCKS drives Src into lipid rafts. (a) Stable MLL/tet-SSeCKS cells grown in the presence or absence of tet were either kept in suspension or adhered to FN-(10 mg/ml) coated plates for 1 h, and after washing with ice-cold PBS, lysates subjected to sucrose gradients were fractionated into heaviest ('bottom' , fraction no. 9) and lightest ('top' , fraction no. 1) as described previously 27 to isolate detergent-resistant caveolin-rich lipid rafts ('light' fractions 4-5). Equal protein aliquots from each fraction were blotted for SSeCKS, Src, FAK poY397 , Cav-1 or Cav-1 poY14 , a known Src phosphorylation site. 76 Cell conditions-A: suspension/tet þ , B: suspension/tet À , C: attached/tet þ , D: attached/tet À , E: Attached/tet À /methyl-b-cyclodextrin (10 mM for 1 h during FN attachment). (b) FRET analysis of CWR22Rv1 cells transiently transfected with Src or FAK kinase activity sensors in the cytosol (Cyto-Src), detergent-insoluble, lipidraft (Lyn-Src or Lyn-FAK) or general membrane sites (KRas-Src), plus either vector FL SSeCKS or SSeCKS(D153-166). Error bars, s.e.; *Po0.01.
Our compatible model (Figure 7) suggests that SSeCKS facilitates the initial Src translocation to caveolin-rich lipid rafts, likely mediated by SSeCKS's N-terminal myristyl group, and possibly acts as a licensing factor for the amount of Src/Cav-1 that might be able to move to focal adhesions. Conditions of SSeCKS deficiency, such as in cancer, would shift more association of Src/Cav-1 to the focal adhesions, resulting in both increased focal adhesion plaque turnover and Cav-1 degradation. Indeed, our data show that MLL cells lacking SSeCKS express roughly twofold lower total Cav-1 protein levels, which are increased after SSeCKS reexpression (Figure 6a, Supplementary Figure S4) , and that SSeCKS reexpression rescues the formation of mature, stable focal adhesion plaques (Figure 2) . Consistent with this model, the reexpression of SSeCKS in adherent MLL induced the translocation of Src to lighter sucrose gradient fractions containing Cav-1 but no FAK poY397 . This enrichment of SSeCKS/Src in lipid rafts resulted in increased relative Cav-1 poY14 levels. In contrast, in the absence of SSeCKS, significant pools of Src and Cav-1 poY14 cofractionated with FAK poY397 , yet almost none was found in the typical lipid-raft fractions. Interestingly, although saturated binding of Cav-1 to Src inhibits its intrinsic kinase activity, 27 binding by SSeCKS does not, and indeed, SSeCKS seems to enhance the ability of Src to phosphorylate Cav-1 in lipid-raft fractions. This implies that the function of Src in lipid rafts is dynamic, depending on subtle interactions with either SSeCKS or Cav-1. Taken together, these data are consistent with a model in which the scaffolding of Src by SSeCKS to caveolin-rich lipid rafts modulates the amount of Src/Cav-1 poY14 that can translocate to FAK-containing focal adhesion complexes, thereby attenuating downstream oncogenic signaling.
MATERIALS AND METHODS
Antibodies (Abs) and reagents
The following primary antibodies (Abs) were used: rabbit polyclonals specific for integrin b1, FAK poY861 , FAK poY925 , MEK1, His-Tag, GAPDH (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or CAS (BD Transduction Laboratories, San Jose, CA, USA) and mouse monoclonal Ab specific for HAepitope tag (Applied Biological Materials, Richmond, BC, Canada), Src, Src poY416 , MEK1/2 poS217/221 , CAS poY165 , Cav-1 poY14 (Cell Signaling Technology, Beverly, MA, USA) or vinculin (Sigma, St Louis, MO, USA). F-actin was stained with rhodamine-phalloidin (Sigma). Caveolae/Rafts isolation kit and methyl-b-cyclodextrin were purchased from Sigma.
Cell culture MLL cell lines expressing tetracycline-regulated (tet OFF ) SSeCKS (MLL/tet-SSeCKS) were described previously. 30 The cells were maintained in Dulbecco's modified Eagle's media supplemented with 10% bovine serum albumin and 0.7 mg/ml tetracycline. CWR22rv1 cells were maintained in RPMI1640 media supplemented with 10% fetal bovine serum.
Adhesion assay
Cell-adhesion experiments were performed as described in Humphries 70 In brief, 96-well microtiter plates were coated with 0.1 ml of ECM (FN, vitronectin, laminin or Col I), incubated at room temperature for 1 h and blocked by 10mg/ml bovine serum albumin at room temperature for 0.5 h after washing. Cells (1.5 Â 10 4 ) were added to each coated well and incubated at 37 1C followed by fixing with 5% glutaraldehyde and staining with crystal violet after two washes. The absorbance of each well was measured at 570 nm. The data were expressed as the mean of triplicate wells. For assessment of cell spreading on ECM, images from adherent cells were taken at 30, 60, 90, and 120 min after seeding. Image J (http://rsbweb.nih.gov/ij/) was used to quantify cell spreading as described by Ross et al. 71 In brief, measurements were taken from at least three different fields of view with a minimum of 10 cells per field. Areas were measured in pixels and the spreading index was determined by standardizing the spreading of cells to the mean size of cells under control conditions.
Haptotaxis assays
Modified Boyden chamber assays were performed to assess haptotaxis by using a polyethylene terephthalate tissue culture insert with 8-mm pores (Becton Dickinson, Franklin Lakes, NJ, USA). A total of 3 Â 10 4 cells in 100 ml of serum-free Dulbecco's modified Eagle's media were seeded atop membranes coated on their bottoms with serum-free ECM protein as an attractant. The cells were allowed to migrate overnight, and cells that had not penetrated the filters were removed by scrubbing with cotton swabs. The chambers were fixed and stained using Diff-Quik Stain Set (Dade Behring Inc., Newark, DE, USA) and examined under a bright-field microscope. Values for migration were obtained by counting six fields of at least 80 cells per field per membrane and represented the average of three independent experiments.
Western blotting MLL/tet-SSeCKS cells grown in the presence or absence of tet (0.7 mg/ml) were plated in 10-cm dishes, serum-starved overnight, trypsinized, resuspended in Dulbecco's modified Eagle's media containing soybean antitrypsin inhibitor (Sigma) and either kept in suspension or replated onto FNcoated dishes (10 mg/ml) for various durations. Cells were lysed in RIPA buffer 56 supplemented with 10 mM Na 3 VO 4 , 1mM NaF and Complete Protease Inhibitor Cocktail (Roche Diagnostics, Mannheim, Germany). In all, 40 mg of total protein per sample was subjected to SDS-PAGE, blotted onto polyvinylidene difluoride membranes, which were blocked for 30 min with 5% bovine serum albumin (Sigma) in 1 Â TBS/T (0.1% Tween-20 in Trisbuffered saline), and then probed and washed as described previously. 56 Digital imaging and signal quantification were performed on a Chemi-Genius Bio-Imager using GeneTools software (Syngene, Frederick, MD, USA). Immunofluorescence analysis MLL/tet-SSeCKS cells plated on glass coverslips (22 mm 2 ) coated with FN for 90 min in the presence or absence of tet were fixed at À 20 1C for 20 min with 60% acetone/3.7% paraformaldehyde in PBS and blocked with 3% non-fat dry milk in PBS for 30 min at room temperature. Cells were incubated with primary Rb-P Abs against integrin b1 (1:100) or FAK (1:150), washed and then incubated with 4 0 , 6-diamidno-2-phenylindole (1:500; Invitrogen, Grand Island, NY, USA) and fluorescein isothiocyanateconjugated goat anti-rabbit IgG (1:250; Chemicon, Temecula, CA, USA). Fluorescent images were captured using Nikon TE2000-E inverted microscope equipped with a Roper CoolSnap HQ CCD camera (Melville, NY, USA).
Cell lines
FAK þ / þ (SSeCKS) or FAK À / À (SSeCKS) expresser cell lines were produced by infecting with pBABE-SSeCKS 25 retrovirus packaged in 293GPG cells 72 
Cell viability
Cell proliferation was evaluated using colorimetric MTS assay (Promega, Madison, WI, USA) that measures restoration of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium to formazan by metabolically active cells. The absorbance of the formazan at 490 nm was determined using a microplate reader in tissue culture medium following 24 h, 48 h and 72 h incubation with or without tet. The results are expressed as mean values ± s.d. for two independent experiments.
Plasmid constructs
SSeCKS constructs containing the D153-166 deletion in either GST-SSeCKS(aa 2-274) or pcDNA3.1/aSSeCKS-green fluorescent protein were produced by a long range inverse PCR technique described previously 73 using '153' and '166' primers containing an SpeI site (underlined): '153' primer 5 0 -ATGCACTAGTGCCAACATCATTAGCCTGGGA-3 0 and '166' primer 5 0 -GCGCACTAGTACGGTGAAGAAGGATAAAAATGAA-3 0 . SSeCKS constructs containing Pro15Ala mutation in either pBABE-SSeCKS or pHis-TAT-SSeCKS 74 were produced by a PCR-mediated mutagenesis (QuikChange Site-Directed Mutagenesis Kit; Stratagene, Santa Clara, CA, USA) using primers: SSeCKS-Pro15AlaF 5 0 -AGCCCCGAGCAGGCGGCGGGGAGCGAC-3 0 and SSeCKS-Pro15AlaR 5 0 -GTCGCTCCCCGCCGCCTGCTCGGGGCT-3 0 .
Pull-down assay
Lysates containing 500 mg of protein from NIH3T3/c-Src cells were incubated with glutathione Sepharose 4B beads bound to GST or various GST-SSeCKS fusion proteins described previously. 65 After washing twice in RIPA buffer, the beads were subjected to western blotting analysis and probed with anti-Src rabbit Ab. Lysates of NIH3T3/c-Src cells were incubated with Ni 2 þ -beads bound to His-SSeCKS (full length or P15A) proteins or glutathione Sepharose 4B beads bound to GST, GST-SSeCKS(aa 2-274) or GST-SSeCKS(aa 2-274, D153-166) proteins. After washing twice in RIPA lysis buffer, the beads were subjected to western blotting analysis and probed with anti-Src rabbit Ab.
Isolation of caveolin-rich membrane fractions
The experiments were performed using a Sigma kit (CS0750) following the manufacturer's protocols. Briefly, MLL/tet-SSeCKS cells incubated overnight with or without tet were kept in suspension or adhered to FN-coated wells (10 mg/ml) for 1 h, washed twice with ice-cold PBS and lysed with Sigma lysis buffer (L7667) containing 1% Triton X-100. The lysates were transferred to a pre-cooled microcentrifuge tube, incubated on ice for 30 min, adjusted to 40% sucrose in lysis buffer and placed on the bottom of an ultracentrifuge tube. A 5-30% linear sucrose gradient was formed above the samples and then centrifuged in an SW41 rotor (Beckman, Brea, CA, USA) at 46 000 r.p.m. for 4 h at 4 1C. A total of 1 ml/fraction was collected across the entire gradient and equal amounts of total protein (40 mg/lane) were analyzed by western blotting. Caveolae were interrupted by treatment with the cholesterol-binding agent methyl-b-cyclodextrin (10 mM) for 1 h during FN stimulation.
FRET analysis
Images were obtained using an inverted Zeiss Axio Observer A1 (Thorwood, NY, USA) equipped with an Andor iXon DV897 backilluminated cooled CCD camera (Andor, South Windsor, CT, USA). The images at the donor emission and acceptor emission were recorded through a Dual View (Photometrics, Tucson, AZ, USA) splitter with doubleband excitation filters. A LED light engine from Lumencor (San Francisco, CA, USA) was used for excitation at wavelengths of 433 nm for the donor and 515 nm for acceptor. FRET ratios were calculated as the energy transfer index: FRET ratio ¼ (I A À I Dbt )/I D , where I A is the peak acceptor emission signal of FRET, I D is the peak donor emission signal and I Dbt is the signal in the acceptor channel due to donor signal bleed-through as described previously. 75 
